Climb Bio, Inc. Common Stock

CLYM

Climb Bio, Inc. (CLYM) is a biotechnology company focused on developing innovative therapies targeting neurodegenerative diseases. The company leverages its proprietary platforms to discover and advance drug candidates aimed at addressing unmet medical needs in neurosciences.

$1.75 +0.05 (3.24%)
🚫 Climb Bio, Inc. Common Stock does not pay dividends

Company News

Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
GlobeNewswire Inc. • Climb Bio, Inc. • October 17, 2025

Climb Bio presented preclinical data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, and long-term clinical data for budoprutug, an anti-CD19 monoclonal antibody showing potential in primary membranous nephropathy treatment.

Related Companies

Euro Tech Holdings Co Ltd. New
Euro Tech Holdings Co Ltd. New
CLWT
Clorox Company
Clorox Company
CLX
Comerica Incorporated
Comerica Incorporated
CMA
Canadian Imperial Bank of Commerce
Canadian Imperial Bank of Commerce
CM